Use of mesenchymal stem cell therapy in COVID-19 related strokes

Coronavirus disease 2019(COVID-19)has affected a broad demographics,eliciting a more significant effect on specific groups such as males,African Americans,and Hispanic minorities.Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies.However,immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19.Mesenchymal stem cell therapy offers regenerative,anti-inflammatory,and immunomodulatory properties that can speed up the recovery from COVID-19.Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from strokes,as COVID-19 increases the risk of strokes due to increased cytokines and clotting factors.Most stroke cases that occur in COVID-19 patients are ischemic strokes.Therefore,with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes,COVID-19-induced stroke patients might benefit from dual-ended treatment.The objective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.